Clinical Trial: Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07239245) titled 'Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo' on Nov. 16.

Brief Summary: This is an open-label, single-arm, multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of TACE combined with Atezolizumab and Bevacizumab as neoadjuvant treatment in Hepatocellular Carcinoma.

Study Start Date: Nov. 10

Study Type: INTERVENTIONAL

Condition: Resectable Hepatocellular Carcinoma With High Risk of Recurrence

Intervention: DRUG: Atezolizumab

Atezolizumab will be administered by IV infusion at a fixed dos...